• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    4.156 +0.066 (+1.61%)
    Streaming Delayed Price Updated: 2:01 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
    Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Provides Business and Operational Update
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Announces Pricing of $42.0 Million Public Offering
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Announces Proposed Public Offering
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.